



## Clinical trial results:

### A Randomized, Open-label, Multicenter, Multiphase Study of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, Administered in Combination with Daratumumab, Compared with Daratumumab Alone in Subjects with Relapsed or Refractory Multiple Myeloma

#### Summary

|                          |                  |
|--------------------------|------------------|
| EudraCT number           | 2017-002611-34   |
| Trial protocol           | BE ES FR GR      |
| Global end of trial date | 19 November 2021 |

#### Results information

|                                |                  |
|--------------------------------|------------------|
| Result version number          | v1 (current)     |
| This version publication date  | 15 December 2022 |
| First version publication date | 15 December 2022 |

#### Trial information

##### Trial identification

|                       |                 |
|-----------------------|-----------------|
| Sponsor protocol code | 54767414MMY2036 |
|-----------------------|-----------------|

##### Additional study identifiers

|                                    |             |
|------------------------------------|-------------|
| ISRCTN number                      | -           |
| ClinicalTrials.gov id (NCT number) | NCT03357952 |
| WHO universal trial number (UTN)   | -           |

Notes:

#### Sponsors

|                              |                                                                                            |
|------------------------------|--------------------------------------------------------------------------------------------|
| Sponsor organisation name    | Janssen Research & Development, LLC                                                        |
| Sponsor organisation address | 920 US Highway 202, Raritan, NJ, United States, 08869-1420                                 |
| Public contact               | Clinical Registry Group, Janssen Research & Development, LLC, ClinicalTrialsEU@its.jnj.com |
| Scientific contact           | Clinical Registry Group, Janssen Research & Development, LLC, ClinicalTrialsEU@its.jnj.com |

Notes:

#### Paediatric regulatory details

|                                                                      |    |
|----------------------------------------------------------------------|----|
| Is trial part of an agreed paediatric investigation plan (PIP)       | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

## Results analysis stage

|                                                      |                  |
|------------------------------------------------------|------------------|
| Analysis stage                                       | Final            |
| Date of interim/final analysis                       | 16 January 2019  |
| Is this the analysis of the primary completion data? | No               |
| Global end of trial reached?                         | Yes              |
| Global end of trial date                             | 19 November 2021 |
| Was the trial ended prematurely?                     | No               |

Notes:

## General information about the trial

Main objective of the trial:

The main objective of this trial was to assess the safety of the combination of JNJ-63723283 and daratumumab and to compare the overall response rate (ORR) in subjects treated with JNJ-63723283 in combination with daratumumab versus daratumumab alone.

Protection of trial subjects:

This study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with Good Clinical Practices and applicable regulatory requirements.

Background therapy: -

Evidence for comparator: -

|                                                           |                  |
|-----------------------------------------------------------|------------------|
| Actual start date of recruitment                          | 16 November 2017 |
| Long term follow-up planned                               | No               |
| Independent data monitoring committee (IDMC) involvement? | Yes              |

Notes:

## Population of trial subjects

### Subjects enrolled per country

|                                      |            |
|--------------------------------------|------------|
| Country: Number of subjects enrolled | Belgium: 4 |
| Country: Number of subjects enrolled | Spain: 1   |
| Country: Number of subjects enrolled | Israel: 5  |
| Worldwide total number of subjects   | 10         |
| EEA total number of subjects         | 5          |

Notes:

### Subjects enrolled per age group

|                                           |   |
|-------------------------------------------|---|
| In utero                                  | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days)                      | 0 |
| Infants and toddlers (28 days-23 months)  | 0 |
| Children (2-11 years)                     | 0 |
| Adolescents (12-17 years)                 | 0 |
| Adults (18-64 years)                      | 6 |
| From 65 to 84 years                       | 4 |

|                   |   |
|-------------------|---|
| 85 years and over | 0 |
|-------------------|---|

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

A total of 10 subjects were enrolled in the study. Among these, 9 subjects were included in the Safety Run-in phase (Part 1) who received daratumumab intravenous (IV) and JNJ-63723283 IV and 1 subject randomised to Arm A in Part 2 of the study who received daratumumab IV alone.

### Period 1

|                              |                                |
|------------------------------|--------------------------------|
| Period 1 title               | Overall Study (overall period) |
| Is this the baseline period? | Yes                            |
| Allocation method            | Randomised - controlled        |
| Blinding used                | Not blinded                    |

### Arms

|                              |                                    |
|------------------------------|------------------------------------|
| Are arms mutually exclusive? | Yes                                |
| <b>Arm title</b>             | Part 1: Daratumumab + JNJ-63723283 |

Arm description:

Subjects in safety run-in cohort received daratumumab 16 milligram per kilogram (mg/kg) intravenously (IV) once every week (Weeks 1 to 8); then once every other week for 16 weeks (Weeks 9 to 24); then once every 4 weeks (Week 25 onwards) and JNJ-63723283 240 milligram (mg) IV during Week 1 on Cycle 1 Day 2, Cycle 1 Day 15, then every 2 weeks thereafter. Each treatment cycle consisted of 28 days. Subjects continued to receive study treatment until confirmed disease progression, unacceptable toxicity, or any other treatment discontinuation criteria were met.

|                                        |                   |
|----------------------------------------|-------------------|
| Arm type                               | Active comparator |
| Investigational medicinal product name | Daratumumab       |
| Investigational medicinal product code |                   |
| Other name                             |                   |
| Pharmaceutical forms                   | Infusion          |
| Routes of administration               | Intravenous use   |

Dosage and administration details:

Subjects received daratumumab 16 mg/kg IV once every week (Weeks 1 to 8); then once every other week for 16 weeks (Weeks 9 to 24); then once every 4 weeks (Week 25 onwards).

|                                        |                 |
|----------------------------------------|-----------------|
| Investigational medicinal product name | JNJ-63723283    |
| Investigational medicinal product code |                 |
| Other name                             |                 |
| Pharmaceutical forms                   | Infusion        |
| Routes of administration               | Intravenous use |

Dosage and administration details:

Subjects received JNJ-63723283 240 mg IV during Week 1 on Cycle 1 Day 2, Cycle 1 Day 15, then every 2 weeks thereafter. Each treatment cycle consisted of 28 days.

|                  |                             |
|------------------|-----------------------------|
| <b>Arm title</b> | Part 2: Daratumumab (Arm A) |
|------------------|-----------------------------|

Arm description:

Subjects in treatment Arm A received daratumumab 16 mg/kg IV once every week (Weeks 1 to 8); then once every other week for 16 weeks (Weeks 9 to 24); then once every 4 weeks (Week 25 onwards). All subjects were continued to receive study treatment until confirmed disease progression, unacceptable toxicity, or any other treatment discontinuation criteria were met.

|          |                   |
|----------|-------------------|
| Arm type | Active comparator |
|----------|-------------------|

|                                        |                                   |
|----------------------------------------|-----------------------------------|
| Investigational medicinal product name | Daratumumab                       |
| Investigational medicinal product code |                                   |
| Other name                             |                                   |
| Pharmaceutical forms                   | Dispersion for infusion, Infusion |
| Routes of administration               | Intravenous use                   |

Dosage and administration details:

Subjects in treatment Arm A received daratumumab 16 mg/kg IV once every week (Weeks 1 to 8); then once every other week for 16 weeks (Weeks 9 to 24); then once every 4 weeks (Week 25 onwards).

| <b>Number of subjects in period 1</b> | Part 1:<br>Daratumumab +<br>JNJ-63723283 | Part 2:<br>Daratumumab (Arm<br>A) |
|---------------------------------------|------------------------------------------|-----------------------------------|
| Started                               | 9                                        | 1                                 |
| Completed                             | 0                                        | 0                                 |
| Not completed                         | 9                                        | 1                                 |
| Sponsor Decision                      | 9                                        | -                                 |
| Withdrawal by Subject                 | -                                        | 1                                 |

## Baseline characteristics

### Reporting groups

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                    |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------|
| Reporting group title                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Part 1: Daratumumab + JNJ-63723283 |
| Reporting group description:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                    |
| Subjects in safety run-in cohort received daratumumab 16 milligram per kilogram (mg/kg) intravenously (IV) once every week (Weeks 1 to 8); then once every other week for 16 weeks (Weeks 9 to 24); then once every 4 weeks (Week 25 onwards) and JNJ-63723283 240 milligram (mg) IV during Week 1 on Cycle 1 Day 2, Cycle 1 Day 15, then every 2 weeks thereafter. Each treatment cycle consisted of 28 days. Subjects continued to receive study treatment until confirmed disease progression, unacceptable toxicity, or any other treatment discontinuation criteria were met. |                                    |
| Reporting group title                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Part 2: Daratumumab (Arm A)        |
| Reporting group description:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                    |
| Subjects in treatment Arm A received daratumumab 16 mg/kg IV once every week (Weeks 1 to 8); then once every other week for 16 weeks (Weeks 9 to 24); then once every 4 weeks (Week 25 onwards). All subjects were continued to receive study treatment until confirmed disease progression, unacceptable toxicity, or any other treatment discontinuation criteria were met.                                                                                                                                                                                                      |                                    |

| Reporting group values                                                            | Part 1:<br>Daratumumab +<br>JNJ-63723283 | Part 2:<br>Daratumumab (Arm<br>A) | Total |
|-----------------------------------------------------------------------------------|------------------------------------------|-----------------------------------|-------|
| Number of subjects                                                                | 9                                        | 1                                 | 10    |
| Title for AgeCategorical<br>Units: subjects                                       |                                          |                                   |       |
| Children (2-11 years)                                                             | 0                                        | 0                                 | 0     |
| Adolescents (12-17 years)                                                         | 0                                        | 0                                 | 0     |
| Adults (18-64 years)                                                              | 5                                        | 1                                 | 6     |
| From 65 to 84 years                                                               | 4                                        | 0                                 | 4     |
| 85 years and over                                                                 | 0                                        | 0                                 | 0     |
| Title for AgeContinuous                                                           |                                          |                                   |       |
| Here, '99999' indicated standard deviation could not be calculated for 1 subject. |                                          |                                   |       |
| Units: years                                                                      |                                          |                                   |       |
| arithmetic mean                                                                   | 63                                       | 43                                |       |
| standard deviation                                                                | ± 10.97                                  | ± 99999                           | -     |
| Title for Gender                                                                  |                                          |                                   |       |
| Units: subjects                                                                   |                                          |                                   |       |
| Female                                                                            | 4                                        | 0                                 | 4     |
| Male                                                                              | 5                                        | 1                                 | 6     |

## End points

### End points reporting groups

|                       |                                    |
|-----------------------|------------------------------------|
| Reporting group title | Part 1: Daratumumab + JNJ-63723283 |
|-----------------------|------------------------------------|

Reporting group description:

Subjects in safety run-in cohort received daratumumab 16 milligram per kilogram (mg/kg) intravenously (IV) once every week (Weeks 1 to 8); then once every other week for 16 weeks (Weeks 9 to 24); then once every 4 weeks (Week 25 onwards) and JNJ-63723283 240 milligram (mg) IV during Week 1 on Cycle 1 Day 2, Cycle 1 Day 15, then every 2 weeks thereafter. Each treatment cycle consisted of 28 days. Subjects continued to receive study treatment until confirmed disease progression, unacceptable toxicity, or any other treatment discontinuation criteria were met.

|                       |                             |
|-----------------------|-----------------------------|
| Reporting group title | Part 2: Daratumumab (Arm A) |
|-----------------------|-----------------------------|

Reporting group description:

Subjects in treatment Arm A received daratumumab 16 mg/kg IV once every week (Weeks 1 to 8); then once every other week for 16 weeks (Weeks 9 to 24); then once every 4 weeks (Week 25 onwards). All subjects were continued to receive study treatment until confirmed disease progression, unacceptable toxicity, or any other treatment discontinuation criteria were met.

### Primary: Number of Subjects With Treatment Emergent Adverse Events (TEAE) in Safety run-in Phase (Part 1)

|                 |                                                                                                                    |
|-----------------|--------------------------------------------------------------------------------------------------------------------|
| End point title | Number of Subjects With Treatment Emergent Adverse Events (TEAE) in Safety run-in Phase (Part 1) <sup>[1][2]</sup> |
|-----------------|--------------------------------------------------------------------------------------------------------------------|

End point description:

An adverse event is any untoward medical event that occurs in a subject administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. TEAEs are adverse events (AEs) which will occur up to 2 years that were absent before treatment or that worsened relative to pre-treatment state. Safety analysis set included all subjects who received at least 1 dose of study agent (JNJ-63723283 or daratumumab, partial or complete) in safety run-in phase of the study.

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Up to 2 years

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive statistics was done, no inferential statistical analysis was performed.

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Endpoint was planned to be analyzed for specified arms only.

| End point values            | Part 1:<br>Daratumumab<br>+ JNJ-<br>63723283 |  |  |  |
|-----------------------------|----------------------------------------------|--|--|--|
| Subject group type          | Reporting group                              |  |  |  |
| Number of subjects analysed | 9                                            |  |  |  |
| Units: Subjects             | 1                                            |  |  |  |

### Statistical analyses

No statistical analyses for this end point

**Primary: Number of Subjects With Dose Limiting Toxicity in Safety run-in Phase (Part 1)**

|                 |                                                                                                  |
|-----------------|--------------------------------------------------------------------------------------------------|
| End point title | Number of Subjects With Dose Limiting Toxicity in Safety run-in Phase (Part 1) <sup>[3][4]</sup> |
|-----------------|--------------------------------------------------------------------------------------------------|

End point description:

Dose limiting toxicity defined as an adverse event or adverse drug reaction experienced by the subjects during observation of 28 days (Part 1) of treatment Cycle 1. Safety analysis set included all subjects who received at least 1 dose of study agent (JNJ-63723283 or daratumumab, partial or complete) in safety run-in phase.

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Cycle 1 (28 days)

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive statistics was done, no inferential statistical analysis was performed.

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Endpoint was planned to be analyzed for specified arms only.

|                             |                                              |  |  |  |
|-----------------------------|----------------------------------------------|--|--|--|
| <b>End point values</b>     | Part 1:<br>Daratumumab<br>+ JNJ-<br>63723283 |  |  |  |
| Subject group type          | Reporting group                              |  |  |  |
| Number of subjects analysed | 9                                            |  |  |  |
| Units: Subjects             | 0                                            |  |  |  |

**Statistical analyses**

No statistical analyses for this end point

**Secondary: Number of Subjects With Treatment Emergent Adverse Events (TEAE) in Part 2**

|                 |                                                                                           |
|-----------------|-------------------------------------------------------------------------------------------|
| End point title | Number of Subjects With Treatment Emergent Adverse Events (TEAE) in Part 2 <sup>[5]</sup> |
|-----------------|-------------------------------------------------------------------------------------------|

End point description:

An adverse event is any untoward medical event that occurs in a subject administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. TEAEs are adverse events (AEs) which will occur up to 2 years that were absent before treatment or that worsened relative to pre-treatment state. Safety analysis set included all subjects who received at least 1 dose of study agent in Part 2 of the study.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Up to 2 years

Notes:

[5] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Endpoint was planned to be analyzed for specified arms only.

|                             |                                   |  |  |  |
|-----------------------------|-----------------------------------|--|--|--|
| <b>End point values</b>     | Part 2:<br>Daratumumab<br>(Arm A) |  |  |  |
| Subject group type          | Reporting group                   |  |  |  |
| Number of subjects analysed | 1                                 |  |  |  |
| Units: Subjects             | 1                                 |  |  |  |

### Statistical analyses

---

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Up to 2 years

|                 |                |
|-----------------|----------------|
| Assessment type | Non-systematic |
|-----------------|----------------|

### Dictionary used

|                 |        |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

|                    |      |
|--------------------|------|
| Dictionary version | 21.0 |
|--------------------|------|

### Reporting groups

|                       |                                    |
|-----------------------|------------------------------------|
| Reporting group title | Part 1: Daratumumab + JNJ-63723283 |
|-----------------------|------------------------------------|

Reporting group description:

Subjects in safety run-in cohort received daratumumab 16 mg/kg IV once every week (Weeks 1 to 8); then once every other week for 16 weeks (Weeks 9 to 24); then once every 4 weeks (Week 25 onwards) and JNJ-63723283 240 milligram (mg) IV during Week 1 on Cycle 1 Day 2, Cycle 1 Day 15, then every 2 weeks thereafter. Each treatment cycle consisted of 28 days. Subjects continued to receive study treatment until confirmed disease progression, unacceptable toxicity, or any other treatment discontinuation criteria were met.

|                       |                             |
|-----------------------|-----------------------------|
| Reporting group title | Part 2: Daratumumab (Arm A) |
|-----------------------|-----------------------------|

Reporting group description:

Subjects in treatment Arm A received daratumumab 16 mg/kg IV once every week (Weeks 1 to 8); then once every other week for 16 weeks (Weeks 9 to 24); then once every 4 weeks (Week 25 onwards). All subjects were continued to receive study treatment until confirmed disease progression, unacceptable toxicity, or any other treatment discontinuation criteria were met.

| Serious adverse events                            | Part 1:<br>Daratumumab +<br>JNJ-63723283 | Part 2:<br>Daratumumab (Arm<br>A) |  |
|---------------------------------------------------|------------------------------------------|-----------------------------------|--|
| Total subjects affected by serious adverse events |                                          |                                   |  |
| subjects affected / exposed                       | 3 / 9 (33.33%)                           | 0 / 1 (0.00%)                     |  |
| number of deaths (all causes)                     | 0                                        | 0                                 |  |
| number of deaths resulting from adverse events    |                                          |                                   |  |
| Nervous system disorders                          |                                          |                                   |  |
| Encephalitis Autoimmune                           |                                          |                                   |  |
| subjects affected / exposed                       | 1 / 9 (11.11%)                           | 0 / 1 (0.00%)                     |  |
| occurrences causally related to treatment / all   | 0 / 1                                    | 0 / 0                             |  |
| deaths causally related to treatment / all        | 0 / 0                                    | 0 / 0                             |  |
| Blood and lymphatic system disorders              |                                          |                                   |  |
| Febrile Neutropenia                               |                                          |                                   |  |
| subjects affected / exposed                       | 1 / 9 (11.11%)                           | 0 / 1 (0.00%)                     |  |
| occurrences causally related to treatment / all   | 0 / 1                                    | 0 / 0                             |  |
| deaths causally related to treatment / all        | 0 / 0                                    | 0 / 0                             |  |
| Renal and urinary disorders                       |                                          |                                   |  |
| Acute Kidney Injury                               |                                          |                                   |  |

|                                                 |                |               |  |
|-------------------------------------------------|----------------|---------------|--|
| subjects affected / exposed                     | 1 / 9 (11.11%) | 0 / 1 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0         |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0         |  |
| Infections and infestations                     |                |               |  |
| Septic Shock                                    |                |               |  |
| subjects affected / exposed                     | 1 / 9 (11.11%) | 0 / 1 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 2          | 0 / 0         |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0         |  |

Frequency threshold for reporting non-serious adverse events: 5 %

| <b>Non-serious adverse events</b>                     | Part 1:<br>Daratumumab +<br>JNJ-63723283 | Part 2:<br>Daratumumab (Arm<br>A) |  |
|-------------------------------------------------------|------------------------------------------|-----------------------------------|--|
| Total subjects affected by non-serious adverse events |                                          |                                   |  |
| subjects affected / exposed                           | 9 / 9 (100.00%)                          | 1 / 1 (100.00%)                   |  |
| Vascular disorders                                    |                                          |                                   |  |
| Hypertension                                          |                                          |                                   |  |
| subjects affected / exposed                           | 2 / 9 (22.22%)                           | 0 / 1 (0.00%)                     |  |
| occurrences (all)                                     | 2                                        | 0                                 |  |
| General disorders and administration site conditions  |                                          |                                   |  |
| Asthenia                                              |                                          |                                   |  |
| subjects affected / exposed                           | 2 / 9 (22.22%)                           | 0 / 1 (0.00%)                     |  |
| occurrences (all)                                     | 2                                        | 0                                 |  |
| Chills                                                |                                          |                                   |  |
| subjects affected / exposed                           | 2 / 9 (22.22%)                           | 0 / 1 (0.00%)                     |  |
| occurrences (all)                                     | 2                                        | 0                                 |  |
| Oedema Peripheral                                     |                                          |                                   |  |
| subjects affected / exposed                           | 1 / 9 (11.11%)                           | 0 / 1 (0.00%)                     |  |
| occurrences (all)                                     | 1                                        | 0                                 |  |
| Influenza Like Illness                                |                                          |                                   |  |
| subjects affected / exposed                           | 1 / 9 (11.11%)                           | 0 / 1 (0.00%)                     |  |
| occurrences (all)                                     | 1                                        | 0                                 |  |
| Fatigue                                               |                                          |                                   |  |
| subjects affected / exposed                           | 3 / 9 (33.33%)                           | 0 / 1 (0.00%)                     |  |
| occurrences (all)                                     | 5                                        | 0                                 |  |
| Pyrexia                                               |                                          |                                   |  |

|                                                  |                     |                    |  |
|--------------------------------------------------|---------------------|--------------------|--|
| subjects affected / exposed<br>occurrences (all) | 1 / 9 (11.11%)<br>1 | 0 / 1 (0.00%)<br>0 |  |
| Respiratory, thoracic and mediastinal disorders  |                     |                    |  |
| Cough                                            |                     |                    |  |
| subjects affected / exposed                      | 2 / 9 (22.22%)      | 0 / 1 (0.00%)      |  |
| occurrences (all)                                | 3                   | 0                  |  |
| Dysphonia                                        |                     |                    |  |
| subjects affected / exposed                      | 1 / 9 (11.11%)      | 0 / 1 (0.00%)      |  |
| occurrences (all)                                | 1                   | 0                  |  |
| Dyspnoea                                         |                     |                    |  |
| subjects affected / exposed                      | 1 / 9 (11.11%)      | 0 / 1 (0.00%)      |  |
| occurrences (all)                                | 1                   | 0                  |  |
| Rhinitis Allergic                                |                     |                    |  |
| subjects affected / exposed                      | 1 / 9 (11.11%)      | 0 / 1 (0.00%)      |  |
| occurrences (all)                                | 1                   | 0                  |  |
| Throat Irritation                                |                     |                    |  |
| subjects affected / exposed                      | 1 / 9 (11.11%)      | 0 / 1 (0.00%)      |  |
| occurrences (all)                                | 1                   | 0                  |  |
| Epistaxis                                        |                     |                    |  |
| subjects affected / exposed                      | 1 / 9 (11.11%)      | 0 / 1 (0.00%)      |  |
| occurrences (all)                                | 1                   | 0                  |  |
| Investigations                                   |                     |                    |  |
| Lipase Increased                                 |                     |                    |  |
| subjects affected / exposed                      | 1 / 9 (11.11%)      | 0 / 1 (0.00%)      |  |
| occurrences (all)                                | 3                   | 0                  |  |
| Weight Decreased                                 |                     |                    |  |
| subjects affected / exposed                      | 1 / 9 (11.11%)      | 0 / 1 (0.00%)      |  |
| occurrences (all)                                | 1                   | 0                  |  |
| Cardiac disorders                                |                     |                    |  |
| Bradycardia                                      |                     |                    |  |
| subjects affected / exposed                      | 1 / 9 (11.11%)      | 0 / 1 (0.00%)      |  |
| occurrences (all)                                | 2                   | 0                  |  |
| Nervous system disorders                         |                     |                    |  |
| Paraesthesia                                     |                     |                    |  |
| subjects affected / exposed                      | 2 / 9 (22.22%)      | 0 / 1 (0.00%)      |  |
| occurrences (all)                                | 2                   | 0                  |  |

|                                                                          |                      |                      |  |
|--------------------------------------------------------------------------|----------------------|----------------------|--|
| Dizziness<br>subjects affected / exposed<br>occurrences (all)            | 1 / 9 (11.11%)<br>1  | 0 / 1 (0.00%)<br>0   |  |
| Blood and lymphatic system disorders                                     |                      |                      |  |
| Anaemia<br>subjects affected / exposed<br>occurrences (all)              | 3 / 9 (33.33%)<br>4  | 0 / 1 (0.00%)<br>0   |  |
| Leukopenia<br>subjects affected / exposed<br>occurrences (all)           | 1 / 9 (11.11%)<br>1  | 0 / 1 (0.00%)<br>0   |  |
| Lymphopenia<br>subjects affected / exposed<br>occurrences (all)          | 2 / 9 (22.22%)<br>12 | 0 / 1 (0.00%)<br>0   |  |
| Neutropenia<br>subjects affected / exposed<br>occurrences (all)          | 4 / 9 (44.44%)<br>13 | 0 / 1 (0.00%)<br>0   |  |
| Thrombocytopenia<br>subjects affected / exposed<br>occurrences (all)     | 3 / 9 (33.33%)<br>18 | 1 / 1 (100.00%)<br>1 |  |
| Ear and labyrinth disorders                                              |                      |                      |  |
| Vertigo<br>subjects affected / exposed<br>occurrences (all)              | 1 / 9 (11.11%)<br>1  | 0 / 1 (0.00%)<br>0   |  |
| Eye disorders                                                            |                      |                      |  |
| Corneal Degeneration<br>subjects affected / exposed<br>occurrences (all) | 1 / 9 (11.11%)<br>1  | 0 / 1 (0.00%)<br>0   |  |
| Gastrointestinal disorders                                               |                      |                      |  |
| Constipation<br>subjects affected / exposed<br>occurrences (all)         | 1 / 9 (11.11%)<br>1  | 0 / 1 (0.00%)<br>0   |  |
| Diarrhoea<br>subjects affected / exposed<br>occurrences (all)            | 2 / 9 (22.22%)<br>2  | 0 / 1 (0.00%)<br>0   |  |
| Nausea<br>subjects affected / exposed<br>occurrences (all)               | 3 / 9 (33.33%)<br>3  | 0 / 1 (0.00%)<br>0   |  |

|                                                                                                                  |                     |                    |  |
|------------------------------------------------------------------------------------------------------------------|---------------------|--------------------|--|
| Dyspepsia<br>subjects affected / exposed<br>occurrences (all)                                                    | 1 / 9 (11.11%)<br>1 | 0 / 1 (0.00%)<br>0 |  |
| Dry Mouth<br>subjects affected / exposed<br>occurrences (all)                                                    | 1 / 9 (11.11%)<br>1 | 0 / 1 (0.00%)<br>0 |  |
| Vomiting<br>subjects affected / exposed<br>occurrences (all)                                                     | 3 / 9 (33.33%)<br>4 | 0 / 1 (0.00%)<br>0 |  |
| Skin and subcutaneous tissue disorders<br>Pruritus<br>subjects affected / exposed<br>occurrences (all)           | 1 / 9 (11.11%)<br>1 | 0 / 1 (0.00%)<br>0 |  |
| Renal and urinary disorders<br>Proteinuria<br>subjects affected / exposed<br>occurrences (all)                   | 1 / 9 (11.11%)<br>1 | 0 / 1 (0.00%)<br>0 |  |
| Musculoskeletal and connective tissue disorders<br>Back Pain<br>subjects affected / exposed<br>occurrences (all) | 1 / 9 (11.11%)<br>1 | 0 / 1 (0.00%)<br>0 |  |
| Myalgia<br>subjects affected / exposed<br>occurrences (all)                                                      | 3 / 9 (33.33%)<br>3 | 0 / 1 (0.00%)<br>0 |  |
| Musculoskeletal Pain<br>subjects affected / exposed<br>occurrences (all)                                         | 1 / 9 (11.11%)<br>1 | 0 / 1 (0.00%)<br>0 |  |
| Muscle Spasms<br>subjects affected / exposed<br>occurrences (all)                                                | 1 / 9 (11.11%)<br>1 | 0 / 1 (0.00%)<br>0 |  |
| Muscle Atrophy<br>subjects affected / exposed<br>occurrences (all)                                               | 1 / 9 (11.11%)<br>1 | 0 / 1 (0.00%)<br>0 |  |
| Myopathy<br>subjects affected / exposed<br>occurrences (all)                                                     | 1 / 9 (11.11%)<br>1 | 0 / 1 (0.00%)<br>0 |  |

|                                         |                |               |  |
|-----------------------------------------|----------------|---------------|--|
| Infections and infestations             |                |               |  |
| Rhinitis                                |                |               |  |
| subjects affected / exposed             | 1 / 9 (11.11%) | 0 / 1 (0.00%) |  |
| occurrences (all)                       | 1              | 0             |  |
| Osteomyelitis                           |                |               |  |
| subjects affected / exposed             | 1 / 9 (11.11%) | 0 / 1 (0.00%) |  |
| occurrences (all)                       | 7              | 0             |  |
| Herpes Simplex                          |                |               |  |
| subjects affected / exposed             | 1 / 9 (11.11%) | 0 / 1 (0.00%) |  |
| occurrences (all)                       | 1              | 0             |  |
| Cellulitis                              |                |               |  |
| subjects affected / exposed             | 1 / 9 (11.11%) | 0 / 1 (0.00%) |  |
| occurrences (all)                       | 1              | 0             |  |
| Body Tinea                              |                |               |  |
| subjects affected / exposed             | 1 / 9 (11.11%) | 0 / 1 (0.00%) |  |
| occurrences (all)                       | 2              | 0             |  |
| Upper Respiratory Tract Infection       |                |               |  |
| subjects affected / exposed             | 1 / 9 (11.11%) | 0 / 1 (0.00%) |  |
| occurrences (all)                       | 1              | 0             |  |
| Vulvovaginal Candidiasis                |                |               |  |
| subjects affected / exposed             | 1 / 9 (11.11%) | 0 / 1 (0.00%) |  |
| occurrences (all)                       | 1              | 0             |  |
| Viral Upper Respiratory Tract Infection |                |               |  |
| subjects affected / exposed             | 1 / 9 (11.11%) | 0 / 1 (0.00%) |  |
| occurrences (all)                       | 1              | 0             |  |
| Metabolism and nutrition disorders      |                |               |  |
| Hyperamylasaemia                        |                |               |  |
| subjects affected / exposed             | 1 / 9 (11.11%) | 0 / 1 (0.00%) |  |
| occurrences (all)                       | 2              | 0             |  |
| Folate Deficiency                       |                |               |  |
| subjects affected / exposed             | 1 / 9 (11.11%) | 0 / 1 (0.00%) |  |
| occurrences (all)                       | 1              | 0             |  |
| Dehydration                             |                |               |  |
| subjects affected / exposed             | 1 / 9 (11.11%) | 0 / 1 (0.00%) |  |
| occurrences (all)                       | 1              | 0             |  |
| Hyperglycaemia                          |                |               |  |

|                             |                |               |  |
|-----------------------------|----------------|---------------|--|
| subjects affected / exposed | 1 / 9 (11.11%) | 0 / 1 (0.00%) |  |
| occurrences (all)           | 1              | 0             |  |
| Hypomagnesaemia             |                |               |  |
| subjects affected / exposed | 1 / 9 (11.11%) | 0 / 1 (0.00%) |  |
| occurrences (all)           | 1              | 0             |  |

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date           | Amendment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 23 August 2017 | <p>Revised DLT criteria</p> <ul style="list-style-type: none"><li>• Revised eligibility criterion for recovery from toxicity from previous immunotherapy treatment</li><li>• Added a criterion for dose delay due to non-immune-related adverse events (AEs).</li><li>• The split first dose of daratumumab was replaced with the full daratumumab 16 milligrams per kilogram (mg/kg) regimen.</li><li>• Clarified that communication with health authorities will occur before proceeding to Part 3.</li><li>• Added a new section regarding study termination for safety considerations.</li></ul>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 20 June 2018   | <p>On 25 May 2018, the sponsor stopped further enrollment into this study, Study 54767414MMY2036, based on safety and efficacy findings in the Study 54767414LUC2001, which combined daratumumab with atezolizumab in non-small cell lung cancer. At the third planned DMC review on 23 May 2018, the DMC reviewed the subject data for the Study 54767414LUC2001. The data monitoring committee (DMC) determined that there was no observed benefit in combination treatment arm (daratumumab+atezolizumab) over atezolizumab alone and recommended stopping enrollment of the study. In addition, the DMC recommended discontinuation of daratumumab treatment to all subjects receiving combination therapy (subjects randomized to the combination Arm B, and subjects randomized to Arm A who had crossed over into Arm B). Although no unexpected imbalances in on-treatment toxicities were observed, the DMC noted a clear early difference in number of deaths between atezolizumab monotherapy arm and combination arm. Discrepancy was observed within first 3 months of start of treatment, where the number of deaths were 4 in the atezolizumab arm and 10 in the combination arm, giving rise to 3-month survival rates of 90.7 percent (%) for the atezolizumab arm and 76.2% for the combination arm. Since the benefit/risk ratio changed for combination therapy in Study 54767414LUC2001, sponsor decided to suspend enrollment into other studies that combine daratumumab and a programmed death-1 (PD-1) or programmed death-ligand 1 (PD-L1) monoclonal antibody (mAb) regardless of indication. In addition to discontinuing enrollment in this study, treatment with the combination of daratumumab and JNJ-63723283 was discontinued and ongoing subjects were given the option to continue on daratumumab monotherapy until subject met one or more of the treatment discontinuation criteria. Assessments and data collection for the new daratumumab monotherapy period were defined and a window for End-of-Treatment (EOT) visit was added.</p> |
| 28 April 2020  | <p>The overall reason for the amendment was to provide flexibility for study investigators to prioritize the safety of their subjects during the global coronavirus (COVID-19) pandemic. To ensure continuity of study treatment, while limiting subjects' time spent at the study center, for subjects who will continue to receive daratumumab intravenous (IV), the duration of infusion may be shortened starting in Cycle 2 onwards to a 90-minute infusion for subjects without a history of an infusion related reaction after the third dose, at the discretion of the investigator. Detailed information regarding daratumumab IV administration, including infusion rates and duration, is removed and will be provided only in the Site Investigational Product Procedures Manual (SIPPM)'.</p>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

Notes:

### Interruptions (globally)

Were there any global interruptions to the trial? No

## Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

1 subject enrolled in Part 2 was not evaluable for efficacy, pharmacokinetics (pk) and immunogenicity endpoints. Hence, these endpoints were not collected. Sponsor suspended enrollment in Part 2 and stopped it early. Part 3 was not conducted.

Notes: